EUVIMEDEUVIMED entdecken
Open Access

Tumor-expressing PD-L1 regulates NT5E expression through MAPK/ERK pathway in triple-negative breast cancer

Cheng Cheng, Chao Shi, Shang Wu, Weixing Wu, Jingping Li, Sinuo Gao, Meng Han, Yimin Wang, Xiangmei Zhang, Yunjiang Liu

Oncology Research · 2025

DOI: 10.32604/or.2025.061637 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Research, 2025. Verfasst von Cheng Cheng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, China. Hauptthemen laut MEDLINE: B7-H1 Antigen, Triple Negative Breast Neoplasms, MAP Kinase Signaling System, 5'-Nucleotidase. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

While programmed cell death 1 (PD-1) inhibitors have improved cancer treatment, the function and mechanisms of programmed cell death ligand 1 (PD-L1), particularly when expressed by cancer cells, remain unclear. This study aims to explore the role of PD-L1 within breast cancer cells and identify key targets for future immunotherapy.

Methods

RNA-seq was performed on breast cancer cells with silenced PD-L1 to screen for differentially expressed genes, followed by bioinformatics analysis. Clinical specimens from breast cancer patients undergoing primary surgery without preoperative treatment were collected, along with in vitro analysis to validate the potential mechanism.

Results

RNA-seq data revealed a significant positive correlation between Ecto-5'-nucleotidase (NT5E) expression and PD-L1. Bioinformatics analysis corroborated this positive correlation. Immunohistochemistry staining demonstrated higher NT5E expression associated with increased lymph node metastasis. High expression of the NT5E gene was associated with poor overall survival (OS) in breast cancer patients, as determined by KM plotter analysis. Following PD-L1 gene silencing by siRNA in breast cancer cells, NT5E mRNA and protein expression significantly decreased. Conversely, no significant changes were observed in PD-L1 expression after NT5E gene silencing. In vitro experiments confirmed that cancer cell proliferation and metastasis abilities were significantly reduced by either PD-L1 or NT5E gene down-regulation. Western blotting demonstrated that PD-L1 expressed by cancer cells regulates NT5E expression through the MAPK/ERK signaling pathway.

Conclusion

This study proposes a potential mechanism wherein tumor-expressing PD-L1 regulates NT5E through the MAPK/ERK pathway. Down-regulation of PD-L1 or NT5E can significantly inhibit the proliferation and metastatic ability of cancer cells, potentially providing practical therapeutic targets and prognostic markers for combined PD-L1 immunotherapy in breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenTriple Negative Breast NeoplasmsMAP Kinase Signaling System5'-NucleotidaseHumansFemaleGene Expression Regulation, NeoplasticCell Line, TumorPrognosisCell ProliferationBiomarkers, TumorMiddle AgedGPI-Linked Proteins

Stichwörter der Autor:innen

Breast cancerERKEcto-5′-nucleotidase (NT5E)MetastasisProgrammed cell death ligand 1 (PD-L1)Proliferation

Substanzen

B7-H1 AntigenCD274 protein, human5'-NucleotidaseNT5E protein, humanBiomarkers, TumorGPI-Linked Proteins

Autor:innen und Institutionen

  • Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
  • Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Hebei Medical University, Shijiazhuang, 050000, China.
  • General Surgery, The First Hospital of Qinhuangdao, Qinhuangdao, 066000, China.
  • Hebei Provincial Cancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, China.

Zitieren

APA

Cheng, C., Shi, C., Wu, S., Wu, W., Li, J., Gao, S., Han, M., Wang, Y., Zhang, X., & Liu, Y. (2025). Tumor-expressing PD-L1 regulates NT5E expression through MAPK/ERK pathway in triple-negative breast cancer. Oncology Research. https://doi.org/10.32604/or.2025.061637

Vancouver

Cheng C, Shi C, Wu S, Wu W, Li J, Gao S, et al. Tumor-expressing PD-L1 regulates NT5E expression through MAPK/ERK pathway in triple-negative breast cancer. Oncology Research. 2025. doi:10.32604/or.2025.061637

BibTeX
@article{Cheng2025,
  author = {Cheng, Cheng and Shi, Chao and Wu, Shang and Wu, Weixing and Li, Jingping and Gao, Sinuo and Han, Meng and Wang, Yimin and Zhang, Xiangmei and Liu, Yunjiang},
  title = {Tumor-expressing PD-L1 regulates NT5E expression through MAPK/ERK pathway in triple-negative breast cancer},
  journal = {Oncology Research},
  year = {2025},
  doi = {10.32604/or.2025.061637}
}
Kostenlos starten →